(Reuters) -The U.S. health regulator on Wednesday approved CorMedix's antimicrobial drug for reduction of catheter-related bloodstream infections (CRBSIs) in patients with kidney disease, allowing the company to launch its first commercial product. The company plans to ready the drug for commercialization by end of the first quarter of 2024, CorMedix CEO Joe Todisco told Reuters. DefenCath, a combination of the antimicrobial active ingredient taurolidine and blood thinner heparin, has previously been rejected twice by the U.S. Food and Drug Administration (FDA) on manufacturing concerns.
KSrelief launches new humanitarian projects in Yemen arabnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from arabnews.com Daily Mail and Mail on Sunday newspapers.
This is the calculator that gives you the average concentration of urea, which is calculated with the value of blood urea nitrogen (BUN), in terms of mg/dl, before and after dialysis
LifeCycle Malta Foundation sets off to NESCAFÉ LifeWalk Challenge 2021 newsbook.com.mt - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsbook.com.mt Daily Mail and Mail on Sunday newspapers.